Pre-made Orticumab benchmark antibody ( Whole mAb, anti-OxLDL therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Orticumab biosimilar, Whole Mab: Anti-OxLDL therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Orticumab (INN) is a human monoclonal antibody that is used as an anti-inflammatory agent and binds to oxLDL. It acts as an immunomodulator.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-412-1mg	1mg	3090
GMP-Bios-ab-412-10mg	10mg	Inquiry
GMP-Bios-ab-412-100mg	100mg	Inquiry
GMP-Bios-ab-412-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Orticumab biosimilar, Whole Mab: Anti-OxLDL therapeutic antibody
INN Name	Orticumab
Target	OxLDL
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2012
Year Recommended	2013
Companies	Abcentra;BioInvent International;Genentech
Conditions Approved	na
Conditions Active	Atherosclerosis;Psoriasis
Conditions Discontinued	na
Development Tech	Human Phage Display